0.6978
price down icon0.81%   -0.003
 
loading
Bioatla Inc stock is traded at $0.6978, with a volume of 263.24K. It is down -0.81% in the last 24 hours and up +0.19% over the past month. BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
See More
Previous Close:
$0.6948
Open:
$0.7068
24h Volume:
263.24K
Relative Volume:
0.27
Market Cap:
$40.73M
Revenue:
-
Net Income/Loss:
$-123.46M
P/E Ratio:
-0.2694
EPS:
-2.59
Net Cash Flow:
$-104.11M
1W Performance:
-9.32%
1M Performance:
+0.19%
6M Performance:
+41.75%
1Y Performance:
-64.10%
1-Day Range:
Value
$0.674
$0.7202
1-Week Range:
Value
$0.6611
$0.80
52-Week Range:
Value
$0.2601
$2.525

Bioatla Inc Stock (BCAB) Company Profile

Name
Name
Bioatla Inc
Name
Phone
858-558-0708
Name
Address
11085 TORREYANA ROAD, SAN DIEGO
Name
Employee
61
Name
Twitter
Name
Next Earnings Date
2025-03-21
Name
Latest SEC Filings
Name
BCAB's Discussions on Twitter

Compare BCAB with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
BCAB
Bioatla Inc
0.6936 40.80M 0 -123.46M -104.11M -2.59
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
425.60 107.66B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
651.49 68.74B 14.25B 4.58B 3.88B 41.77
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
456.05 58.93B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
ARGX
Argen X Se Adr
820.89 50.51B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
INSM
Insmed Inc
189.47 41.29B 398.11M -1.03B -868.57M -5.7032

Bioatla Inc Stock (BCAB) Upgrades & Downgrades

Date Action Analyst Rating Change
Aug-13-25 Downgrade Citizens JMP Mkt Outperform → Mkt Perform
Nov-13-24 Downgrade H.C. Wainwright Buy → Neutral
Sep-15-22 Initiated JMP Securities Mkt Outperform
May-05-22 Downgrade Credit Suisse Outperform → Neutral
Mar-21-22 Initiated H.C. Wainwright Buy
Oct-15-21 Resumed BTIG Research Buy
Jun-28-21 Initiated ROTH Capital Buy
May-05-21 Resumed Credit Suisse Outperform
Apr-26-21 Resumed Credit Suisse Outperform
Jan-11-21 Initiated BTIG Research Buy
Jan-11-21 Initiated Credit Suisse Outperform
Jan-11-21 Initiated JP Morgan Overweight
Jan-11-21 Initiated Jefferies Buy
View All

Bioatla Inc Stock (BCAB) Latest News

pulisher
06:50 AM

Is BioAtla Inc. a candidate for recovery play2025 Analyst Calls & Consistent Profit Trading Strategies - newser.com

06:50 AM
pulisher
06:47 AM

Sentiment analysis tools applied to BioAtla Inc.2025 Trading Recap & Technical Entry and Exit Alerts - newser.com

06:47 AM
pulisher
06:01 AM

Why BioAtla Inc. stock is favored by top institutions2025 Big Picture & Safe Capital Growth Trade Ideas - newser.com

06:01 AM
pulisher
06:01 AM

Analyzing BioAtla Inc. with risk reward ratio chartsLayoff News & Verified Short-Term Plans - newser.com

06:01 AM
pulisher
05:55 AM

Will BioAtla Inc. continue its uptrendQuarterly Profit Review & Consistent Income Trade Ideas - newser.com

05:55 AM
pulisher
05:34 AM

How supply chain issues affect BioAtla Inc. stockAnalyst Upgrade & Weekly High Conviction Ideas - newser.com

05:34 AM
pulisher
05:30 AM

Chart overlay techniques for tracking BioAtla Inc.Gold Moves & Low Drawdown Trading Strategies - newser.com

05:30 AM
pulisher
05:04 AM

Measuring BioAtla Inc.’s beta against major indicesWeekly Trade Report & Weekly High Potential Stock Alerts - newser.com

05:04 AM
pulisher
12:50 PM

What moving averages say about BioAtla Inc.2025 EndofYear Setup & Expert Verified Movement Alerts - newser.com

12:50 PM
pulisher
12:45 PM

What to do if you’re stuck in BioAtla Inc.Weekly Trade Report & Weekly Breakout Stock Alerts - newser.com

12:45 PM
pulisher
Oct 28, 2025

Why BioAtla Inc. stock is a value investor pickWeekly Risk Summary & Advanced Technical Signal Analysis - Fundação Cultural do Pará

Oct 28, 2025
pulisher
Oct 27, 2025

BioAtla’s Phase 1 Study on BA3182: A New Hope for Advanced Adenocarcinoma - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Can BioAtla Inc. stock sustain institutional interest2025 Big Picture & Capital Protection Trade Alerts - Fundação Cultural do Pará

Oct 27, 2025

Bioatla Inc Stock (BCAB) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$37.55
price up icon 1.68%
$93.49
price up icon 0.98%
$28.59
price down icon 0.30%
$103.95
price down icon 0.63%
biotechnology ONC
$312.06
price up icon 1.26%
$189.15
price down icon 2.59%
Cap:     |  Volume (24h):